{"schema_version":"secwatch.filing_event.v1","accession":"0001778922-26-000033","form_type":"8-K","ticker":"SGP","cik":"0001778922","company_name":"SpyGlass Pharma, Inc.","filed_at":"2026-05-14T20:15:16+00:00","discovered_at":"2026-05-14T20:16:00.250105+00:00","generated_at":"2026-05-14T20:53:35.722937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SpyGlass Pharma reports Q1 loss of $13.8M; Phase 1/2 BIM-IOL data shows 98% drop-free, 34% IOP reduction","bullets":["Net loss of $13.8M ($0.69/share) vs $8.8M loss in Q1 2025; R&D expenses $8.5M, G&A $6.9M.","Cash & investments $251M as of Mar 31, 2026, funded through 2028 after $172.5M IPO in Feb 2026.","Phase 1/2 BIM-IOL 12-mo data: 98% drop-free, 34% mean IOP reduction from baseline at 78-mcg dose.","Phase 3 registrational trials SGP-005 and SGP-006 continue; enrollment completion expected in 2027.","Bimatoprost Drug Ring (BIM-DRS) first-in-human trial on track to start H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001778922-26-000033","json":"https://secwatch.observer/filing/0001778922-26-000033.json","markdown":"https://secwatch.observer/filing/0001778922-26-000033.md","text":"https://secwatch.observer/filing/0001778922-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/0001778922-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/sgp-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:53:35.722937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"646fc809fc0d5ecf66c417e0aecc3b56aef730c0","claim":"SpyGlass Pharma, Inc. reported first quarter ended March 31, 2026 results: net income $13.8 million, EPS ($0.69) per basic and diluted share.","evidence_excerpt":"Net Loss was $13.8 million, or ($0.69) per basic and diluted share, for the first quarter of 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/0001778922-26-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Net income","value":"$13.8 million"},{"label":"EPS","value":"($0.69) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}